ROCKVILLE, Md. (PRWEB) May 14, 2019
IMMUNE 3D®, a privately held biotechnology company, announced today an expansion of their business strategy beyond immuno-oncology into areas of autoimmunity, fibrosis and skin immunology. In addition, the company will leverage its proprietary, matched autologous human T cell and tumor cell lines for IO discovery efforts.
IMMUNE 3D®’s proprietary platform aims to study factors that affect immune migration under complex physiological conditions. The company utilizes the platform in areas of drug target discovery, characterization, biomarker identification and drug delivery testing.
"The increase in preclinical research and development spending has steered biopharmaceutical companies towards finding cost-effective alternatives beyond traditional in vivo models,” said Vik Subbu, Founder and CEO of IMMUNE 3D®. “This has paved the way for ex vivo platforms such as IMMUNE 3D® to be used across areas of preclinical studies and translational drug development.“
"IMMUNE 3D® provides unique insights into the tumor immune-microenvironment. Importantly, this platform can assess the efficacy of a wide variety of therapeutic approaches beyond immune checkpoints including the evaluation of CAR-T therapies in solid tumors,” said Dr. Tonya Webb, Associate Professor of Microbiology and Immunology, at the University of Maryland, Baltimore and scientific advisor to IMMUNE 3D®.
IMMUNE 3D® aims to build on its extensive know-how and intellectual property to develop proprietary 3D models across broad immune-mediated diseases. The company has profiled targets that facilitate immune migration using its proprietary human T cell and tumor cell lines. These targets have the potential to serve as novel therapies across a variety of human disorders such as cancer, autoimmunity and infectious diseases.
About IMMUNE 3D®
IMMUNE 3D®'s proprietary platform, provides a unique and powerful tool to interrogate immunobiology of diseases. The Company’s mission is to shift the paradigm towards a wider use of 3D cultures in translational research while accelerating much needed drug candidates into the clinic. The company has assembled a network of key opinion leaders, academic partnerships, board members and industry scientists to advance its platform.